Evaluation of effect of hybrid bioartificial liver using end-stage liver disease model

Table 1 General data of patients

No	Sex	Age(yr)	Diagnosis	Multi-organs failure	Outcome
1	Female	43	ALF, HBV	Liver, brain	Spontaneous recovery
2	Male	31	SALF, HBV	Liver, brain	Recovery spontaneous
3	Male	33	SALF, HBV and alcoholic liver disease	Liver, coagulopathy, cardiovascular	Orthotopic liver transplantation
4	Female	27	ALF, drug induced liver injury	Liver, brain	Death
5	Male	31	ALF, HBV	Liver, kidney	Death

ALF: Acute liver failure; SALF: Sub-acute liver failure; HBV: Hepatitis B virus.

Table 2 Changes of partial biochemical indices pre- and post-treatment of HBL(mean ± SD)

Item	TBIL (mg/dL)	NH3 (µg/dL)	ALB (g/L)	CHE (U/L)	PTA%
Pre-treatment	23.08 ± 12.50	116.6 ± 23.1	29.79 ± 4.35	3801.5 ± 1710.6	17.25 ± 10.11
Post-treatment at 0 h	12.34 ± 4.39b	98.3 ± 19.5	32.57 ± 4.76	5560.9 ± 1067.6a	38.60 ± 10.25b
Post-treatment at 24 h	14.10 ± 6.08b	103.2 ± 23.5	33.13 ± 4.34	5438.5 ± 1024.3a	34.31 ± 11.75a
Post-treatment at 72 h	17.24 ± 8.34a	110.8 ± 30.6	31.42 ± 4.07	5676.2 ± 957.9a	35.20 ± 9.78b

^aP < 0.05,

^bP < 0.01, vs pre-treatment. TBIL: Total bilirubin; NH_3: Serum ammonia; ALB: Albumin; CHE: Cholinesterase; PTA: Pro-thrombin activity.

Table 3 Changes of MELD score before and after treatment of HBL

Patients	Before-treatment						After-treatment
	1	2	3	4	5	mean ± SD	1	2	3	4	5	mean ± SD
PTA%	22.4	21	18	11	14.37	17.35 ± 4.7	40.2	43	45	30.1	18.2	35.3 ± 20.87
INR	2.42	2.51	2.61	4.14	3.74	3.08 ± 1.27	1.58	1.55	1.5	2.08	2.71	1.8 ± 1.02
Creatinine (mg/dL)	13	16.9	7.9	16.6	42.4	19.36 ± 15.3	5.9	5	4.3	8.9	35.2	11.8 ± 13.1
Bilirubin (mg/dL)	20.4	17	15.1	22.2	40.46	23.03 ± 10.1	20.4	17	15.1	22.2	40.46	17.4 ± 12.66
MELD	41	41	41	47	48	43.6	34	33	32	39	45	33.6